**Amendments to the Claims**:

The following listing of claims will replace all prior versions, and listings, of claims in the application:

1. (Cancelled)

2. (Original) Pharmaceutical composition comprising at least one inhibitor of twist gene expression or of the activity of the corresponding protein and at least one pharmaceutically acceptable excipient.

3. (Original) Method for the prognosis and/or diagnosis, in vitro, of a cancer using a biological sample taken from a patient, according to which the expression of the twist gene is determined.

4. (Original) Method for the prognosis and/or diagnosis of a cancer according to Claim 3, comprising the following steps:

   a. a biological sample from the patient is provided and biological material is extracted from the biological sample,

   b. at least one reagent specific for the twist gene is provided,

   c. the expression of the twist gene is determined.

5. (Currently Amended) Method according to ~~Claim 3 or 4~~ Claim 3, ~~characterized in that~~ wherein the biological sample taken from the patient is a tissue or blood sample.

6. (Currently Amended) Method according to ~~any one of Claims 3 to 5~~ Claim 3, ~~characterized in that~~ wherein the cancer is chosen from neuroblastoma or breast cancer.

7. (Original) Kit for the diagnosis and/or prognosis of a cancer, comprising at least one reagent specific for the twist gene.

8. (New) Method according to Claim 4, wherein the biological sample taken from the patient is a tissue or blood sample.

9. (New) Method according to Claim 4, wherein the cancer is chosen from neuroblastoma or breast cancer.

10. (New) Method according to Claim 5, wherein the cancer is chosen from neuroblastoma or breast cancer.

11. (New) Method according to Claim 8, wherein the cancer is chosen from neuroblastoma or breast cancer.

12. (New) Method of treating cancer, comprising administering to a patient in need of such treatment at least one inhibitor of twist gene expression or of the activity of the corresponding protein.